statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Novo Nordisk Shares Decline Amid Competitive Pressure

Novo Nordisk A/S Common Stock (NYSE: NVO) experienced a notable decline on Thursday. This movement follows a significant announcement from competitor Viking Therapeutics Inc. (NASDAQ:VKTX).
read more...

EU greenlights Wegovy for lowering heart risks

Novo Nordisk's popular weight loss drug Wegovy just got backing from the European Union's medical regulator to expand its use to include reducing the risk of serious heart events for people who are...

Why Viking's Weight-Loss Drug News Is Weighing on Eli Lilly, Novo Nordisk Stocks

picture alliance / Contributor / Getty Images

 Key TakeawaysEli Lilly and Novo Nordisk shares lost ground Thursday, while shares of Viking Therapeutics soared after the company reported...

An Ozempic rival is getting closer to market   and it's hurting Novo Nordisk and Eli Lilly stock

Shares of Novo Nordisk and Eli Lilly slid Thursday after San Diego-based Viking Therapeutics announced that it's advancing an experimental weight loss drug to a late-stage clinical trial.Read more...

Viking Therapeutics Unveils Monthly Weight-Loss Shot, And Rocks Eli Lilly, Novo Nordisk

Viking Therapeutics Unveils Monthly Weight-Loss Shot, And Rocks Eli Lilly, Novo Nordisk...

Novo Nordisk's Stock Dips In Pre-Market Despite Winning UK's Approval Of Weight Loss Drug: What's Going On

Wegovy, a GLP-1 receptor agonist, had previously been approved for use in obesity treatment and weight management.
read more...

Novo Nordisk's Wegovy weight loss drug wins UK approval for use as a heart treatment

The U.K.'s health regulator on Tuesday approved the use of Novo Nordisk's Wegovy drug to reduce the risk of obese adults suffering from serious heart problems or strokes...

Oral Weight Loss Drugs Vs. Injections - Pills Are Promising Yet Challenging Frontier

Pharmaceutical giants like Roche, Eli Lilly, Novo Nordisk, and Pfizer are racing to develop oral weight loss medications. These drugs promise to complement existing injectables, offering new hope in...

Novo Nordisk Advances Share Buyback Program

Novo Nordisk (NVO) has released an update. Novo Nordisk A/S, a leading global healthcare company, has actively pursued its share repurchase program...

Hims & Hers has a 'long future' in selling off-brand Ozempic, former Novo Nordisk executive says

The millennial-skewed telehealth platform Hims & Hers announced Monday that it has added K re Schultz, a longtime Novo Nordisk executive, to its board of directors.Read more...

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Volume	3.18M
52-Wk High	$148.15
52-Wk Low	$77.96

NVO Novo Nordisk A/S

About

Feed

News

Sentiment

Earnings

Fundamentals